Andrew Combs Purchases 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) insider Andrew Combs purchased 60,000 shares of the stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $1.37 per share, with a total value of $82,200.00. Following the completion of the acquisition, the insider now directly owns 377,623 shares of the company's stock, valued at approximately $517,343.51. This represents a 18.89 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Andrew Combs also recently made the following trade(s):

• On Friday, December 20th, Andrew Combs acquired 3,075 shares of Prelude Therapeutics stock. The shares were bought at an average cost of $1.15 per share, with a total value of $3,536.25.

Prelude Therapeutics Price Performance

PRLD stock traded up $0.21 during midday trading on Thursday, hitting $1.40. The company's stock had a trading volume of 429,571 shares, compared to its average volume of 211,715. The company's fifty day moving average price is $1.16 and its 200 day moving average price is $3.10. Prelude Therapeutics Incorporated has a twelve month low of $0.80 and a twelve month high of $6.80. The stock has a market capitalization of $77.05 million, a P/E ratio of -0.79 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. The company had revenue of $3.00 million during the quarter. Equities analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PRLD shares. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a report on Friday, November 8th. JMP Securities reissued a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Institutional Investors Weigh In On Prelude Therapeutics

Several large investors have recently made changes to their positions in the stock. Barclays PLC lifted its position in shares of Prelude Therapeutics by 86.0% in the third quarter. Barclays PLC now owns 27,165 shares of the company's stock valued at $57,000 after buying an additional 12,564 shares during the last quarter. XTX Topco Ltd bought a new stake in Prelude Therapeutics in the 3rd quarter valued at $100,000. Dimensional Fund Advisors LP lifted its holdings in Prelude Therapeutics by 103.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company's stock valued at $111,000 after purchasing an additional 14,769 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company's stock worth $133,000 after purchasing an additional 15,682 shares during the period. Finally, Walleye Capital LLC increased its holdings in shares of Prelude Therapeutics by 446.2% in the third quarter. Walleye Capital LLC now owns 83,175 shares of the company's stock valued at $172,000 after purchasing an additional 67,946 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company's stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.